Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
- 6 July 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 8637-8648
Abstract
Objective: To evaluate the efficacy and safety of tubeless hybrid closed‐loop (HCL) systems in type 1 diabetes (T1D). Methods: We searched Web of Science, PubMed, Scopus, and Embase from inception to April 1 st , 2026 for randomized controlled trials (RCTs) comparing tubeless HCL systems with standard care (SC; sensor‐augmented pumps [SAP] or multiple daily injections [MDI] + continuous glucose monitoring [CGM]). Primary efficacy outcomes were time in range of 3.9–10.0 mmol/L (TIR) and glycated haemoglobin (HbA1c). Secondary efficacy outcomes included time above range (TAR10.0, TAR13.9), time below range (TBR3.9, TBR3.0), and coefficient of variability (CV). Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA) risks. Random‐ or fixed‐effects models were used as appropriate. Results: Four RCTs involving 514 participants were included. The mean age was 32.3 ± 15.7 years, with a mean T1D duration of 14.7 ± 11.1 years, and with mean baseline HbA1c 8.0% ± 1.0%. Three studies compared tubeless HCL with SAP, and one with MDI + CGM. Compared with SC, tubeless HCL improved TIR (MD = 15.31%, 95% CI [7.67%, 22.95%], I 2 = 95%, p < 0.001) and HbA1c (MD = −0.46%, 95% CI [−0.79%, −0.14%], I 2 = 91%, p = 0.005). Lower levels of TAR (TAR10.0, TAR13.9), TBR3.9 and CV were also observed (all p < 0.001) in tubeless HCL group. No significant differences were observed in TBR3.0 (MD = −0.06%, 95% CI [−0.17%, 0.06%], I 2 = 71%, p = 0.35) and insulin dose. DKA and SH events were rare in both groups. Conclusions: The available evidence suggests that tubeless HCL systems may improve glycaemic control without increasing insulin dose or short‐term safety risks. Head‐to‐head trials using identical algorithms are needed to isolate form‐factor‐specific effects.Keywords
Funding Information
- National Natural Science Foundation of China (82501081)
This publication has 27 references indexed in Scilit:
- Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trialThe Lancet Diabetes & Endocrinology, 2026
- Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?Diabetes & Metabolism, 2025
- Experience of People with Diabetes Treated with Insulin Delivery Systems in France: A Comparative Analysis of Multiple Daily Injections, Tubeless Pumps, Tubed Pumps, and Hybrid Closed LoopsDiabetes Therapy, 2024
- Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta‐AnalysisDiabetes/Metabolism Research and Reviews, 2024
- Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trialDiabetologia, 2024
- Care, control and complications of hospitalised patients with type 1 diabetes in China: A nationwide‐based registry studyDiabetes/Metabolism Research and Reviews, 2024
- Open-Source Automated Insulin Delivery in Type 1 DiabetesNew England Journal of Medicine, 2022
- Patch Pumps: What are the advantages for people with diabetes?Diabetes Research and Clinical Practice, 2022
- A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery SystemDiabetes Technology & Therapeutics, 2021
- Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic reviewDiabetic Medicine, 2013